Global Information
회사소개 | 문의 | 위시리스트

중국의 긴급 수요용 해외 수입 신약 검열 및 승인 절차 최신 가이드북(2019년판)

Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition)

리서치사 Access China Management Consulting
발행일 2019년 03월 상품 코드 803191
페이지 정보 영문 49 Pages
가격
US $ 750 ₩ 896,000 PDF by E-mail (Single User License)
US $ 3,500 ₩ 4,183,000 PDF by E-mail (2-5 User License)
US $ 5,250 ₩ 6,275,000 PDF by E-mail (Site License)
US $ 15,000 ₩ 17,931,000 PDF by E-mail (Global License)


중국의 긴급 수요용 해외 수입 신약 검열 및 승인 절차 최신 가이드북(2019년판) Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition)
발행일 : 2019년 03월 페이지 정보 : 영문 49 Pages

중국의 긴급 수요용 해외 수입 신약 검열 및 승인 절차에 관한 규제에 대해 조사했으며, 해외/다국적 의약품 제조업체가 중국의 판매 허가를 순조롭게 획득하기 위한 가이던스를 제공합니다.

제1장 주요 요약

제2장 중국의 의료 시장 환경과 빠르게 변화하는 규제 프레임워크 : 해외/다국적 의약품 및 의료기기 제조업체가 갖추어야 할 예비 지식

  • 중국의 변화하는 의료 시장 환경
  • 급속한 규제 프레임워크 변화를 촉진하는 원인은?

제3장 긴급 수요용 해외 수입 신약 검열 및 승인 절차 의약품 유형

제4장 의약품 유형 선정

제5장 긴급 수요용 해외 수입 신약 검열 및 승인 절차

제6장 필요한 신청자료

제7장 중국의 의약품 PM(Post-marketing)에 관한 해외 신청자의 의무

제8장 의약품 R&D 및 기술 검열을 위한 커뮤니케이션 및 교환에 관한 규제 : 우선 검열 및 승인 절차를 위한 전용 경로에 진입하기 위한 중요한 첫 단계

  • 커뮤니케이션 및 정보교환의 일반 규제
  • CDE와의 정보교환 회의를 여는 제안과 심의
  • 정보교환 회의 준비
  • 정보교환 회의 개최
  • 정보교환 회의 신청폼, 서류 및 회의록 템플릿

제9장 긴급 수요용 해외 수입 신약 리스트

LSH 19.03.22

China is one of the fastest growing global economies with one fifth population in the world. Nowadays, China has become the world's second largest healthcare market after the United States. Facing a gigantic population and rapid population aging, the Chinese government accelerated the priority approval of innovative drugs and relaxed the market access for overseas drugs to cope with the clinical urgent demand. In recent years, China's fast-track approval time is much shorter than any other country, which attracts more and more overseas pharmaceutical manufacturers to enter into the Chinese healthcare market. Undoubtedly the Chinese healthcare market of nearly 1.4 billion populations is a huge business opportunities for the overseas pharmaceutical manufacturers.

The Chinese “National Medical Products Administration (NMPA)” and the “National Health Commission (NHC)” jointly issued the latest “Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand” on October 23, 2018, which provided a dedicated pathway for priority review and approval of overseas drugs importing to Chinese healthcare market and clarified the specific review and approval procedures.

To capture the huge business opportunities of the Chinese healthcare market and seize a larger part of Chinese healthcare market, how do the foreign pharmaceutical manufacturers in compliance with the latest “Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand”? How do the overseas pharmaceutical manufacturers operate business smoothly in China? The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs need a thorough knowledge of the latest regulations for priority review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand. The Chinese regulatory approach is unique.

The Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition) is an essential resource for overseas and multinational pharmaceutical manufacturers to successfully acquire the marketing authorization in China, which provided a detailed guidance for comprehensive knowledge of the latest regulations on review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand to navigate regulatory requirements step by step.

This guidebook is organized as follows. Chapter 2 provides a latest description of the Chinese changing healthcare market landscape and rapidly changing regulatory framework as background for audience. Chapter 3 introduces that review and approval procedures of overseas imported new drugs of Chinese clinical urgent demand are applicable to what scope of drug varieties. Chapter 4 expounds the selection process of drug varieties. Chapter 5 elaborates the details of review and approval procedures of overseas imported new drugs of Chinese clinical urgent demand. Chapter 6 expounds the Chinese drug regulatory authority's requirements for application materials that overseas applicants apply for overseas imported new drugs of Chinese clinical urgent demand. Chapter 7 expounds the duties and obligations of overseas pharmaceutical manufacturers for drugs exported to Chinese healthcare market. Chapter 8 elaborates the Chinese drug regulatory authority's latest “Administrative Measures for Communication and Exchange on Drug Research and Development and Technical Review and Approval” to guide the overseas applicants to take the key first step entry into the dedicated pathway of priority review and approval procedures and to smoothly pass the review and approval procedures. Chapter 9 exhibits the first batch list of overseas imported new drugs of Chinese clinical urgent demand that has been selected by the Chinese drug regulatory authority, which is calling the overseas applicants to submit the application for marketing in China to the Chinese drug regulatory authority, also let the overseas pharmaceutical manufacturers understand the Chinese drug regulatory authority's distinctive regulatory current status.The list covers 40 drug varieties that have been approved to market in the United States, EU or Japan but that have not been yet marketed in China, and involves with 33 overseas pharmaceutical manufacturers.

The audiences of this guidebook are the overseas pharmaceutical manufacturers wishing to enter into the Chinese healthcare market, and the multinational pharmaceutical manufacturers have penetrated into the Chinese healthcare market, as well as their senior executive officers engaging in regulatory affairs expecting to understand the latest regulations on review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand. After having skimmed through this guidebook, audiences can clearly acquire a comprehensive and thorough knowledge of the latest regulations on priority review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand. Access China Management Consulting Ltd hopes this guidebook, based on the full and accurate regulations, can guide the overseas and multinational pharmaceutical manufacturers to achieve a successful entry into the Chinese healthcare market, and smoothly operate their companies in China.

Table of Contents

Chapter 1: Executive Summary

Chapter 2: China's Changing Healthcare Market Landscape and Rapidly Changing Regulatory Framework: A knowledge Background for Overseas and Multinational Pharmaceutical Manufacturers

  • 2.1. China's Changing Healthcare Market Landscape
  • 2.2. What is Cause to Drive the Rapid Change of Regulatory Framework?

Chapter 3: Scope of Drug Variety for Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand

Chapter 4: Drug Variety Selection

Chapter 5: Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand

Chapter 6: Requirements for Application Materials

Chapter 7: Overseas Applicants' Duties and Obligations for Drugs on Post-marketing in China

Chapter 8: Regulations on Communication and Exchange for Drug R&D and Technical Review and Approval: Key First Step to Successfully Enter the Dedicated Pathway for Priority Review and Approval Procedures

  • 8.1. General Regulations of Communication and Exchange
  • 8.2. Proposing and Deliberating Convene the Communication and Exchange Meetings with the CDE
  • 8.3. Preparation for Communication and Exchange Meetings
  • 8.4. Convening Communication and Exchange Meetings
  • 8.5. Application Form, Materials and Minutes Template of Communication and Exchange Meeting
  • Annex 1: Application Form of Communication and Exchange Meeting
  • Annex 2: The Materials for Communication and Exchange Meeting
  • Annex 3: Communication and Exchange Meeting Minutes Template

Chapter 9: A List of Overseas Imported New Drugs for Chinese Clinical Urgent Demand

  • Table 9. List of Overseas Imported Drugs for Chinese Clinical Urgent Demand (The First Batch)

List of Tables

  • Annex 1: Application Form of Communication and Exchange Meeting
  • Annex 2: The Materials for Communication and Exchange Meeting
  • Annex 3: Communication and Exchange Meeting Minutes Template
  • Table 9: List of Overseas Imported Drugs for Chinese Clinical Urgent Demand (The First Batch)

Companies Mentionned:

  • Janssen Biotech, Inc.
  • BioMarin Pharmaceutical Inc.
  • Actelion Pharmaceuticals Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Novartis Pharmaceuticals Corporation
  • Amgen Europe B.V.
  • Ariad Pharmaceuticals Inc.
  • Takeda Pharmaceuticals U.S.A., Inc.
  • Genzyme Corp
  • Novartis Pharma K.K.
  • Eli Lilly and Company
  • CELGENE CORP
  • Shire Orphan Therapies GmbH
  • Acorda Therapeutics Inc.
  • Genentech Inc.
  • Celgene Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Prestwick Pharmaceuticals, Inc.
  • Dyax Corp.
  • Shire Human Genetic Therapies Inc.
  • Pfizer Ltd.
  • Aegerion Pharmaceuticals Inc.
  • United Therapeutics Corporation
  • Biogen Idec Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • EUSA Pharma (UK) Limited
  • Dompe Farmaceutici, s.p.a.
  • Ultragenyx Pharmaceutical Company
  • GlaxoSmithKline Biologicals S.A.
  • Spark Therapeutics, Inc.
  • Cardiome UK Limited
  • Merck Sharp & Dohme Corp.
  • Gilead Sciences Inc.
Back to Top
전화 문의
F A Q